- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Pelacarsen (TQJ230)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 65 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 5:06 AM EDT